Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of dexmedetomidine, glycopyrrolate, and isoproterenol is not specifically described in the provided search results. Isoproterenol (also known as isoprenaline) is a sympathomimetic medication primarily used for treating bradycardia, heart block, and cardiac arrest. It works by stimulating β-adrenergic receptors (both β1 and β2), which increases heart rate and the force of heart contractions. Common side effects of isoproterenol include: headache, dizziness, nervousness, nausea, blurred vision, tremors, sweating, flushing, tachycardia, palpitations, and anxiety. More serious side effects may include: chest pain, severe arrhythmias, hypertension or hypotension, shortness of breath, and pulmonary edema. Isoproterenol is typically administered intravenously for bradycardia or heart block, and sometimes via inhalation for respiratory conditions. In the past, it was also administered under the tongue or into the rectum. Dexmedetomidine is an alpha-2 adrenergic receptor agonist used for sedation in intensive care settings and during procedures. Glycopyrrolate is an anticholinergic medication often used to reduce secretions and block certain vagal effects during anesthesia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexmedetomidine + glycopyrrolate + isoproterenol.